Pyramid Analytics added to the DoD’s Tradewind Solutions Marketplace
8.6.2023 16:07:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, is pleased to announce that its Pyramid Decision Intelligence Platform has been added to the Tradewind Solutions Marketplace, DoD’s digital environment of post-competition, readily awardable, technology solution pitch videos. The Tradewind Solutions Marketplace is the flagship offering of Tradewind, DoD’s suite of tools and services designed to accelerate the procurement and adoption of AI/ML, digital, and data analytics solutions across the DoD. Tradewind sits in the DoD’s Chief Digital Artificial Intelligence Office (CDAO).
The Pyramid Platform provides comprehensive, advanced analytics capabilities, including data pipelines and preparation (with embedded machine learning), enterprise and self-service data analytics, dashboarding (with built-in AI and chat-bots), and data science.
Pyramid’s platform was rated as “Awardable” and added to the Tradewind Solutions Marketplace. Solutions selected for the Marketplace, including the Pyramid Decision Intelligence Platform, have been assessed and vetted through competitive procedures, which satisfy the competition requirements of the Federal Acquisition Regulation (FAR), the Defense Federal Acquisition Regulation Supplement (DFARS), and the Statutes, Policies, and guidance applicable to the DoD’s Other Transaction Authorities.
Key points
- Pyramid’s platform is now listed on the Tradewind Solutions Marketplace, DoD’s digital platform for sourcing AI/ML, digital, and data analytics solutions.
- The DoD and the broader Defense Industrial Base has continued needs for low-code/no-code solutions that provide advanced analytics visualizations, machine learning, self-service analytics, natural language queries, and augmented and artificial intelligence.
- The Pyramid Platform received top ratings in leading analyst firm Gartner’s 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
- Pyramid’s US Federal Practice is led by a team of experienced leaders, including Joe Fritsch, Director of Federal Sales; Peter Morris, Senior Director of Partner Channel, North America; Dave Henry, Senior Vice President, Strategic Alliances; Russ Cosentino, Regional Vice President Sales, North America, East; and Brian McCormac, Senior Vice President of Global Sales.
“Being added to the Tradewind Solutions Marketplace is a significant recognition of the quality and relevance of our platform to the current and future needs of the defense industry. The Pyramid Decision Intelligence Platform offers comprehensive capabilities to support government agencies’ AI/ML, digital, and data analytics needs, enabling them to make faster and more informed decisions,” said Joe Fritsch, Director of Federal Sales at Pyramid Analytics.
In October 2022, Pyramid announced a new business practice dedicated to the US federal market, led by Joe Fritsch, and a strategic partnership with Carahsoft, The Trusted Government IT Solutions Provider®. This new DoD marketplace listing has strengthened its commitment to providing critical decision intelligence to government agencies.
The Pyramid Decision Intelligence Platform is already used by other government agencies, including the U.S. Department of Veterans Affairs, where it provides advanced analytics capabilities to over 50,000 users to help the VA manage, assess, and deliver quality healthcare to veterans across all VA hospitals.
Pyramid’s addition to the Tradewind Solutions Marketplace marks another significant milestone in the company’s dedication to helping U.S. federal civilian, defense, and intelligence agencies expand and optimize their use of data-informed decision intelligence at scale.
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics USA is the U.S.-based subsidiary of Pyramid Analytics B.V. that is incorporated in Amsterdam with regional operations in global innovation and business centers, including New York City, London, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
For additional information on the Pyramid offerings in the Tradewind Solutions Marketplace, interested Government parties can log in at https://www.tradewindai.com/ and search for “Pyramid Analytics.” Registration is required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005227/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom